Cancer of Breast Clinical Trial
Official title:
Perioperative Oral Nutrition Supplementation in Malnourished Surgical Cancer Patients- A Randomized Controlled Trial
Verified date | August 2021 |
Source | International Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to evaluate the effectiveness of perioperative oral nutrition supplementation (ONS) on nutritional status in malnourished cancer patients undergoing elective surgery. The hypothesis is pre-operative ONS feeding in malnourished surgical cancer patients is effective on improving nutritional status. An extended period of 3 months post-operative ONS feeding is effective on improving nutritional status as compared to ONS feeding post-operatively during hospital stay only. Perioperative feeding is effective on improving secondary outcomes such as sleep quality, post-operative complications and length of hospital stay.
Status | Completed |
Enrollment | 91 |
Est. completion date | June 30, 2021 |
Est. primary completion date | June 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years to 65 Years |
Eligibility | Inclusion Criteria: - Male or female from all ethnicity - 25 to 65 years - BMI not less than 18.0 kg/m² - Cancer patients who are confirmed with elective surgery whose co-morbidities are stabilized based on the ASA Physical Status Classification System ASA Class 1 and 2 - Fulfil at least two characteristics of AND/ ASPEN Diagnosis of Malnutrition These characteristics are insufficient energy intake, weight loss, loss of muscle mass, loss of subcutaneous fat, localized or generalized fluid accumulation and diminished functional status as measured by handgrip strength. Exclusion Criteria: - Patients who require enteral or parenteral feeding - Pregnant or lactating - On chemotherapy or radiotherapy - Total gastrectomy or ileostomy - Metastasized cancer, upper gastrointestinal cancer, terminal diseases, decompensated liver or renal disease, major concurrent metabolic problem such as uncontrolled diabetes, dementia - On regular steroids prescription |
Country | Name | City | State |
---|---|---|---|
Malaysia | International Medical University | Kuala Lumpur |
Lead Sponsor | Collaborator |
---|---|
International Medical University | Kotra Pharma (M) Sdn Bhd |
Malaysia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in body weight | Anthropometry measurement | Change from baseline body weight at 4 months | |
Primary | Change in body mass index (BMI) | Anthropometry measurement | Change from baseline body mass index (BMI) at 4 months | |
Primary | Change in serum albumin level | Serum albumin is an indicator of protein stores to assess nutritional status | Change from baseline serum albumin level at 4 months | |
Primary | Change in serum pre-albumin level | Serum pre-albumin is an indicator of protein stores to assess nutritional status | Change from baseline serum pre-albumin level at 4 months | |
Secondary | Change in handgrip force | Handgrip force is a measure of handgrip strength by dynamometer | Change from baseline handgrip force at 4 months | |
Secondary | Change in muscle mass | Muscle mass reported in kilogram is measured by bioelectrical impedance analyser | Change from baseline muscle mass at 4 months | |
Secondary | Change in fat mass | Fat mass reported in kilogram is measured by bioelectrical impedance analyser | Change from baseline fat mass at 4 months | |
Secondary | Change in serum transferrin level | Serum transferrin is a measure of nutritional status | Change from baseline serum transferrin level at 4 months | |
Secondary | Change in hemoglobin level | Serum hemoglobin is a measure of nutritional status | Change from baseline hemoglobin level at 4 months | |
Secondary | Change in high sensitivity c-reactive protein (HsCRP) level | High sensitivity c-reactive protein (HsCRP) is a measure of inflammatory status | Change from baseline high sensitivity c-reactive protein (HsCRP) level at 4 months | |
Secondary | Change in Interleukin-6 (IL-6) | Interleukin-6 (IL-6) is a measure of inflammatory status | Change from baseline Interleukin-6 (IL-6) at 4 months | |
Secondary | Change in salivary cortisol level | Salivary cortisol level is a biological marker of stress reaction | Change from baseline salivary cortisol level at 4 months | |
Secondary | Change in energy intake | Energy intake reported in calories is a dietary measure to assess nutritional status | Change from baseline energy intake at 4 months | |
Secondary | Change in protein intake | Protein intake reported in gram is a dietary measure to assess nutritional status | Change from baseline protein intake at 4 months | |
Secondary | Change in Pittsburgh Sleep Quality Index (PSQI) scores | Pittsburgh Sleep Quality Index (PSQI) scores range from 0-42.Higher scores indicate poorer sleep quality | Change from baseline Pittsburgh Sleep Quality Index (PSQI) scores at 4 months | |
Secondary | Presence of post-surgical complications | Post-surgical complications are indicated by presence of wound infection, chest infection and use of antibiotics, responses are either yes or no | Change from baseline post-surgical complications at 3 months | |
Secondary | Length of hospital stay | Number of days participants are admitted into the hospital | Up to 5 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03285607 -
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
|
Phase 1 | |
Completed |
NCT02225470 -
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
|
Phase 3 | |
Withdrawn |
NCT05191004 -
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
|
Phase 1/Phase 2 | |
Completed |
NCT01271738 -
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
|
N/A | |
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Completed |
NCT01980823 -
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer
|
Early Phase 1 | |
Completed |
NCT02658708 -
Bright Light on Fatigue in Women Being Treated for Breast Cancer
|
Phase 1 | |
Completed |
NCT02891681 -
Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
|
N/A | |
Completed |
NCT05584644 -
A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
|
||
Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03084536 -
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
|
Phase 2 | |
Terminated |
NCT02907918 -
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
|
Phase 2 | |
Completed |
NCT03007979 -
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
|
Phase 2 | |
Terminated |
NCT02462200 -
Shave Margins in Breast Conservation Therapy
|
Phase 2 | |
Completed |
NCT03592121 -
Study to Investigate the Effect of AB-101 in Breast Cancer Survivors
|
Early Phase 1 | |
Terminated |
NCT02642094 -
Aging Mammary Stem Cells and Breast Cancer Prevention
|
Phase 2 | |
Active, not recruiting |
NCT04855552 -
Telehealth Weight Loss Program for Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT05364450 -
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
|
N/A | |
Completed |
NCT03494400 -
Aerobic Training in Treatment for Breast Cancer
|
N/A | |
Terminated |
NCT02375048 -
Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI
|
Phase 2 |